Evidence map›Paper›PMID 35760307›Full record

ArticleBone2022

Induction of a NOTCH3 Lehman syndrome mutation in osteocytes causes osteopenia in male C57BL/6J mice.

E Canalis, S P Yee, A N Economides, L Schilling, J Yu

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bone, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

E CanalisDepartment of Orthopaedic Surgery, UConn Health, Farmington, CT 06030, United States; Department of Medicine, UConn Health, Farmington, CT 06030, United States; UConn Musculoskeletal Institute, UConn Health, Farmington, CT 06030, United States. Electronic address: canalis@uchc.edu.
S P YeeDepartment of Cell Biology, UConn Health, Farmington, CT 06030, United States.
A N EconomidesRegeneron Pharmaceuticals, Tarrytown, NY 10531, United States.
L SchillingUConn Musculoskeletal Institute, UConn Health, Farmington, CT 06030, United States.
J YuDepartment of Orthopaedic Surgery, UConn Health, Farmington, CT 06030, United States; UConn Musculoskeletal Institute, UConn Health, Farmington, CT 06030, United States.
UConn Health · USRegeneron (United States) · US

Funding

The Skeleton of Lateral Meningocele SyndromeR01AR072987 · NIAMS · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI CANALIS, ERNESTO · 2018 to 2023
$2.2M
NIAMS NIH HHS R01 AR072987
6 · The paper itself

Abstract

Lateral Meningocele or Lehman Syndrome (LMS) is associated with NOTCH3 mutations causing deletions of the PEST domain and a gain-of-NOTCH3 function. We demonstrated that Notch3

Indexed as

Bone Diseases, MetabolicMeningoceleAbnormalities, MultipleAnimalsEndothelial CellsMaleMiceMice, Inbred C57BLMutationOsteocytesReceptors, NotchReceptors, NotchLateral meningocele syndromeLehman syndromeMouse geneticsNotch3Notch pathwayOsteocyteOsteopenia

Identifiers

PMID35760307
PMCPMC10870228
OpenAlexW4283517709

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.